This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study
comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE)
recurrence and bleeding in patients with cancer associated VTE (ASTER)
Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by
high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two
most common treatments today are low molecular weight heparin (LMWH) and direct
anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are
seen as a more convenient alternative though associated with bleeding risk; further, some
cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable
pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with
abelacimab monthly administration to apixaban twice daily administration over a 6-month
treatment. The study outcomes include VTE recurrence, bleeding event and treatment
discontinuation at 6 months
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.